Cesare Michele Iacovitti, Marco Cuzzocrea, Alessio Rizzo, Matteo Bauckneht, Roberto C Delgado Bolton, Gaetano Paone, Giorgio Treglia
{"title":"Diagnostic value of dual-tracer PET/CT with [<sup>18</sup>F]FDG and PSMA ligands in prostate cancer: an updated systematic review.","authors":"Cesare Michele Iacovitti, Marco Cuzzocrea, Alessio Rizzo, Matteo Bauckneht, Roberto C Delgado Bolton, Gaetano Paone, Giorgio Treglia","doi":"10.3389/fmed.2025.1607227","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prostate-specific membrane antigen (PSMA) ligand PET/CT has significantly improved prostate cancer (PCa) imaging. However, in patients with poorly differentiated PCa or neuroendocrine transdifferentiation, [<sup>18</sup>F]fluorodeoxyglucose ([<sup>18</sup>F]FDG) PET/CT may provide additional diagnostic information. This systematic review evaluates the diagnostic value of combining [<sup>18</sup>F]FDG PET/CT with PSMA ligand PET/CT in PCa patients.</p><p><strong>Methods: </strong>A systematic literature search of studies assessing the added diagnostic value of dual-tracer [<sup>18</sup>F]FDG and PSMA ligands PET/CT in PCa patients was conducted using PubMed/MEDLINE and Cochrane Library databases and available information was summarized.</p><p><strong>Results: </strong>Fourteen studies (<i>n</i> = 901 patients) met the inclusion criteria. The dual-tracer approach identified [<sup>18</sup>F]FDG-positive/PSMA-negative (FDG+/PSMA-) lesions in a subset of patients, particularly those with Gleason Score (GS) ≥ 9. However, in patients with GS < 8, [<sup>18</sup>F]FDG PET/CT did not significantly improve lesion detection over PSMA ligand PET/CT alone.The presence of FDG+/PSMA- lesions correlated with aggressive tumor biology, increased risk of metastases, and worse prognosis.</p><p><strong>Conclusion: </strong>Literature data showed that [<sup>18</sup>F]FDG PET/CT may serve as a valuable complementary imaging modality for high risk PCa patients potentially influencing staging and treatment decisions. Future prospective studies are warranted to further elucidate the prognostic significance and cost-effectiveness of combining [<sup>18</sup>F]FDG PET/CT with PSMA ligand PET/CT in PCa patients.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1607227"},"PeriodicalIF":3.1000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283616/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1607227","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Prostate-specific membrane antigen (PSMA) ligand PET/CT has significantly improved prostate cancer (PCa) imaging. However, in patients with poorly differentiated PCa or neuroendocrine transdifferentiation, [18F]fluorodeoxyglucose ([18F]FDG) PET/CT may provide additional diagnostic information. This systematic review evaluates the diagnostic value of combining [18F]FDG PET/CT with PSMA ligand PET/CT in PCa patients.
Methods: A systematic literature search of studies assessing the added diagnostic value of dual-tracer [18F]FDG and PSMA ligands PET/CT in PCa patients was conducted using PubMed/MEDLINE and Cochrane Library databases and available information was summarized.
Results: Fourteen studies (n = 901 patients) met the inclusion criteria. The dual-tracer approach identified [18F]FDG-positive/PSMA-negative (FDG+/PSMA-) lesions in a subset of patients, particularly those with Gleason Score (GS) ≥ 9. However, in patients with GS < 8, [18F]FDG PET/CT did not significantly improve lesion detection over PSMA ligand PET/CT alone.The presence of FDG+/PSMA- lesions correlated with aggressive tumor biology, increased risk of metastases, and worse prognosis.
Conclusion: Literature data showed that [18F]FDG PET/CT may serve as a valuable complementary imaging modality for high risk PCa patients potentially influencing staging and treatment decisions. Future prospective studies are warranted to further elucidate the prognostic significance and cost-effectiveness of combining [18F]FDG PET/CT with PSMA ligand PET/CT in PCa patients.
期刊介绍：
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
